MAP1LC3A and Parkinson disease: Fibroblasts from PD patients with PRKN mutations (PRKN-PD) showed increased levels of LC3 in a study assessing only one patient [78], while decreased levels of LC3 were reported in another study assessing seven PRKN-PD patients [79].